CD3E: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of CD3E. The page also collects GeneMedi's different modalities and formats products for CD3E in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD3E target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

The protein encoded by this gene is the CD3-epsilon polypeptide, which together with CD3-gamma, -delta and -zeta, and the T-cell receptor alpha/beta and gamma/delta heterodimers, forms the T-cell receptor-CD3 complex. This complex plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. The genes encoding the epsilon, gamma and delta polypeptides are located in the same cluster on chromosome 11. The epsilon polypeptide plays an essential role in T-cell development. Defects in this gene cause immunodeficiency. This gene has also been linked to a susceptibility to type I diabetes in women. [provided by RefSeq, Jul 2008]

Pre-made CD3E-specific INN-index biosimilar (antibody&conjugates)-Mosunetuzumab, dafsolimab setaritox, Talquetamab, Visilizumab, Obrindatamab, Cibisatamab, Odronextamab, Runimotamab, Glofitamab, Ubamatamab, Etevritamab, Elranatamab, Vepsitamab, Plamotamab, Emerfetamab, Otelixizumab, Teplizumab, Pavurutamab, Voxalatamab, Tidutamab, Vibecotamab, Vixtimotamab, Epcoritamab, Acapatamab, Blinatumomab, Zolimomab, Gresonitamab, Pacanalotamab, Pasotuxizumab, Dafsolimab, catumaxomab, muromonab-CD3, Muromonab, Flotetuzumab, Eluvixtamab, Tarlatamab, Tepoditamab, Nivatrotamab, Alnuctamab, Solitomab, ertumaxomab, Teclistamab, Foralumab, Tebentafusp, Duvortuxizumab

Anti-CD3E therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.	Products Name (INN Index)	INN Name	Previous Name	Target	Format	Order
GMP-Bios-ab-356	Pre-Made Mosunetuzumab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody	Mosunetuzumab		CD3E;MS4A1/CD20	Bispecific mAb
GMP-Bios-INN-790	Pre-Made Dafsolimab Setaritox Biosimilar, Whole Mab Adc, Anti-Cd3E Antibody: Anti-CD3epsilon/IMD18/T3E/TCRE therapeutic antibody Drug Conjugate	dafsolimab setaritox		CD3E	Whole mAb ADC
GMP-Bios-ab-546	Pre-Made Talquetamab biosimilar, Bispecific mAb, Anti-GPRC5D;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody	Talquetamab		GPRC5D;CD3E	Bispecific mAb
GMP-Bios-ab-622	Pre-Made Visilizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody	Visilizumab		CD3E	Whole mAb
GMP-Bios-ab-386	Pre-Made Obrindatamab biosimilar, Bispecific scFv with Domain Crossover, Anti-CD276;CD3E Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 therapeutic antibody	Obrindatamab		CD276;CD3E	Bispecific scFv with Domain Crossover
GMP-Bios-ab-104	Pre-Made Cibisatamab biosimilar, Bispecific mAb with Domain Crossover: Anti-CEACAM5;CD3E therapeutic antibody	Cibisatamab		CEACAM5;CD3E	Bispecific mAb with Domain Crossover
GMP-Bios-ab-391	Pre-Made Odronextamab biosimilar, Bispecific mAb, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody	Odronextamab		MS4A1/CD20;CD3E	Bispecific mAb
GMP-Bios-ab-500	Pre-Made Runimotamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;CD3E Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;T3E/TCRE/IMD18 therapeutic antibody	Runimotamab		ERBB2/HER2;CD3E	Bispecific mAb
GMP-Bios-ab-248	Pre-Made Glofitamab biosimilar, Bispecific mAb with Domain Crossover, Anti-CD3E;MS4A1/CD20 antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7therapeutic antibody	Glofitamab		CD3E;MS4A1/CD20	Bispecific mAb with Domain Crossover
GMP-Bios-ab-705	Pre-Made Ubamatamab biosimilar, Whole mAb, Anti-MUC16;CD3E Antibody: Anti-CA125;T3E/TCRE/IMD18 therapeutic antibody	Ubamatamab		MUC16;CD3E	Bispecific Whole mAb
GMP-Bios-ab-197	Pre-Made Etevritamab biosimilar, Bispecific scFv, Anti-EGFR;CD3E Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;T3E/TCRE/IMD18 therapeutic antibody	Etevritamab		EGFR;CD3E	Bispecific scFv
GMP-Bios-ab-663	Pre-Made Elranatamab biosimilar, Whole mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody	Elranatamab		TNFRSF17;CD3E	Bispecific Whole mAb
GMP-Bios-ab-708	Pre-Made Vepsitamab biosimilar, Whole mAb, Anti-MUC17;CD3E Antibody: Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 therapeutic antibody	Vepsitamab		MUC17;CD3E	Bispecific scFv-scFv-scFc
GMP-Bios-ab-446	Pre-Made Plamotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody	Plamotamab		MS4A1/CD20;CD3E	Bispecific Mixed mAb and scFv
GMP-Bios-ab-176	Pre-Made Emerfetamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody	Emerfetamab		CD33;CD3E	Bispecific scFv
GMP-Bios-ab-414	Pre-Made Otelixizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody	Otelixizumab		CD3E	Whole mAb
GMP-Bios-ab-562	Pre-Made Teplizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody	Teplizumab		CD3E	Whole mAb
GMP-Bios-ab-433	Pre-Made Pavurutamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody	Pavurutamab		TNFRSF17;CD3E	Bispecific scFv
GMP-Bios-ab-709	Pre-Made Voxalatamab biosimilar, Whole mAb, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody	Voxalatamab		FOLH1/GCPII;CD3E	Bispecific Whole mAb
GMP-Bios-ab-570	Pre-Made Tidutamab biosimilar, Bispecific Mixed mAb and scFv, Anti-SSTR2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody	Tidutamab		SSTR2;CD3E	Bispecific Mixed mAb and scFv
GMP-Bios-ab-619	Pre-Made Vibecotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody	Vibecotamab		IL3RA;CD3E	Bispecific Mixed mAb and scFv
GMP-Bios-ab-624	Pre-Made Vixtimotamab biosimilar, Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)), Anti-CD3E;CD33 Antibody: Anti-T3E/TCRE/IMD18;p67/SIGLEC3/SIGLEC-3 therapeutic antibody	Vixtimotamab		CD3E;CD33	Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)
GMP-Bios-ab-189	Pre-Made Envafolimab biosimilar, Single Domain Variable Fragment;H, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 therapeutic antibody	Epcoritamab		CD3E;MS4A1/CD20	Bispecific mAb
GMP-Bios-ab-006	Pre-Made Acapatamab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody	Acapatamab		FOLH1/GCPII;CD3E	Bispecific scFv
GMP-Bios-ab-074	Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody	Blinatumomab		CD19;CD3E	Bispecific T-Cell Engager
GMP-Bios-ab-650	Pre-Made Zolimomab biosimilar, Whole mAb, Anti-CD5 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody	Zolimomab		CD5	Whole mAb
GMP-Bios-ab-670	Pre-Made Gresonitamab biosimilar, Whole mAb, Anti-CLDN18;CD3E Antibody: Anti-SFTA5/SFTPJ;T3E/TCRE/IMD18 therapeutic antibody	Gresonitamab		CLDN18;CD3E	Bispecific scFv-scFv-scFc
GMP-Bios-ab-421	Pre-Made Pacanalotamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody	Pacanalotamab		TNFRSF17;CD3E	Bispecific scFv
GMP-Bios-ab-429	Pre-Made Pasotuxizumab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody	Pasotuxizumab		FOLH1/GCPII;CD3E	Bispecific scFv
GMP-Bios-ab-130	Pre-Made Dafsolimab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody	Dafsolimab		CD3E	Whole mAb
GMP-Bios-INN-772	Pre-Made Catumaxomab Biosimilar, Bispecific, Anti-Cd3E; Epcam Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody	catumaxomab		CD3E;EPCAM	Bispecific
GMP-Bios-INN-921	Pre-Made Muromonab-Cd3 3Iosimilar, Whole Mab, Anti-Cd3E Antibody: Anti-CD3epsilon/IMD18/T3E/TCRE therapeutic antibody	muromonab-CD3		CD3E	Whole  mAb
GMP-Bios-ab-360	Pre-Made Muromonab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody	Muromonab		CD3E	Whole mAb
GMP-Bios-ab-218	Pre-Made Flotetuzumab biosimilar, Bispecific scFv with Crossover, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibody	Flotetuzumab		IL3RA;CD3E	Bispecific scFv with Crossover
GMP-Bios-ab-173	Pre-Made Eluvixtamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody	Eluvixtamab		CD33;CD3E	Bispecific scFv
GMP-Bios-ab-552	Pre-Made Tarlatamab biosimilar, Bispecific scFv, Anti-DLL3;CD3E Antibody: Anti-SCDO1;T3E/TCRE/IMD18 therapeutic antibody	Tarlatamab		DLL3;CD3E	Bispecific scFv
GMP-Bios-ab-563	Pre-Made Tepoditamab biosimilar, Bispecific mAb, Anti-CLEC12A/CD371;CD3E Antibody: Anti-CLL-1/CLL1/DCAL-2/MICL;T3E/TCRE/IMD18 therapeutic antibody	Tepoditamab		CLEC12A/CD371;CD3E	Bispecific mAb
GMP-Bios-ab-380	Pre-Made Nivatrotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-GD2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody	Nivatrotamab		GD2;CD3E	Bispecific Mixed mAb and scFv
GMP-Bios-ab-018	Pre-Made Alnuctamab biosimilar, Bispecific mAb with Domain Crossover, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody	Alnuctamab		TNFRSF17;CD3E	Bispecific mAb with Domain Crossover
GMP-Bios-ab-528	Pre-Made Solitomab biosimilar, Bispecific scFv, Anti-EPCAM;CD3E Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1;T3E/TCRE/IMD18 therapeutic antibody	Solitomab		EPCAM;CD3E	Bispecific scFv
GMP-Bios-INN-845	Pre-Made Ertumaxomab Biosimilar, Bispecific, Anti-Cd3E;Erbb2 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	ertumaxomab		CD3E;ERBB2	Bispecific
GMP-Bios-ab-557	Pre-Made Teclistamab biosimilar, Bispecific mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody	Teclistamab		TNFRSF17;CD3E	Bispecific mAb
GMP-Bios-ab-220	Pre-Made Foralumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody	Foralumab		CD3E	Whole mAb
GMP-Bios-ab-555	Pre-Made Tebentafusp biosimilar, scFv Fusion, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody	Tebentafusp		CD3E	scFv Fusion
GMP-Bios-ab-161	Pre-Made Duvortuxizumab biosimilar, Bispecific scFv with Crossover, Anti-CD19;CD3E antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody	Duvortuxizumab		CD19;CD3E	Bispecific scFv with Crossover

Pre-made anti-CD3E inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-CD3E benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD3E mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.	Antibody Name	Format	Classified by tag	Order
GM-Tg-hg-T87075-Ab	Anti-CD3E monoclonal antibody	mab	Biofunctional antibody, Therapeutics Target antibody